ABSTRACT
In this research antimicrobial activity of nanoparticles ZnO on perilous bacteria such as
Pseudomonas aeruginosa was evaluated. P. aeruginosa is important pathogen that caused burn wound
infections as it is multi-drug resistant and has several virulence factors. Fifteen samples of P.
aeruginosa were collected from patients who suffering from Burn infections in Al-Hilla teaching
hospital burn unit with the age range between (7-80) years old for both genders. After collecting burn
samples, the diagnosis and characterization were performed by culturing and biochemical tests. ZnO
NPs were synthesized by chemical method, Zinc oxide nanoparticles are well-known to be one of the
multifunctional inorganic compounds which are widely used in medical applications. This study aims
to prepare ZnO nanoparticles with particle size ranging from 23-29 nm. In the present study, surface
modification of ZnO nanoparticles was performed, and influence of modification of the structure and
morphological properties was investigated. The resulting nanoparticles were characterized by X-ray
diffraction (XRD), scanning electron microscopy (SEM) and atomic force (AFM). Zinc oxide
nanoparticles with the average diameter of about 29 nm were modified with an oleic acid to exert
more compatibility. From the results obtained it is suggested that modified ZnO-nanoparticles could
be used effectively in safety environmental and medical applications. Antibacterial activity for
nanoparticle ZnO against P. aeruginosa isolates was measured by: Agar Diffusion Technique and
Minimum Inhibitory Concentration (MIC)/Minimum bactericidal Concentration (MBC) with
microdilution. The best zone of inhibition was (35.5mm) at a concentration of 40 μg/ml of nano-ZnO
in one strain of P. aeruginosa while the lowest inhibition zone was (16 mm) at a concentration of 20
μg/ml of nano ZnO in one strain also. In addition, all P. aeruginosa isolates were completely inhibited
at the concentration of 3.7 μg/ml of nano-ZnO (MIC) but no significant antibacterial activity was
observed at concentrations less than 1.8 μg/ml of nano-ZnO and the (MBC) was same as MIC (3.7
μg/ml) for all P.aeruginosa isolates.
References
[1] Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of
bacterial resistance. Int J Antimicrob Ag. 2001; 17: 357-363.
[2] Gajjar P, Pettee B, Britt DW, Huang W, Johnson WP, Anderson J. Antimicrobial
activities of commercial nanoparticles against an environmental soil microbe,
Pseudomonas putida KT2440. Journal of Biological Engineering. 2009; 3: 9-22.
[3] Reddy KM, Feris K, Bell J, Wingett DG, Hanley C, Punnoose A. Selective toxicity of
zinc oxide nanoparticles to prokaryotic and eukaryotic systems. Applied physics letters.
2007; 90(21): 213902-3.
[4] Sawai J. Quantitative evaluation of antibacterial activities of metallic oxide powders
(ZnO, MgO and CaO) by conductimetric assay. Journal of Microbiological Methods.
2003; 54(2): 177-82.
[5] Chwalibog A., Sawosz E., Hotowy A., Szeliga J., Mitura S., Mitura K., Grodzik M.,
Orlowski P. and Sokolowska, A. (2010): Visualization of interaction between inorganic
nano-particles and bacteria or fungi. International Journal of Nanomedicine, 5, 1085-
1094.
[6] Pati R, Mehta RK, Mohanty S, Padhi A, Sengupta M, Vaseeharan B, et al. Topical
application of zinc oxide nanoparticles reduces bacterial skin infection in mice and
exhibits antibacterial activity by inducing oxidative stress response and cell membrane
disintegration in macrophages. Nanomedicine. 2014; 10(6): 1195-208.
[7] Baxter J. B. and Aydil E.S. (2005): Nanowire based dye sensitized solar cells. Appl.
Phys. Lett. 86, 53114, 2005.
[8] Klasen, H. (2000). A Historical Review of the Use of Silver in the Treatment of Burns.
II. Renewed Interest for Silver, Burns, 26, pp. 131-138.
[9] Landsdown, A.B. (2006). Silver in Health Care: Antimicrobial Effects and Safety in
Use, Curr. Probl. Dermatol, 33, pp. 17-34.
[10] Fong, J. & Wood, F. (2006). Nanocrystalline Silver Dressing in Wound Management: A
Review, International Journal of Nanomedicine, 1(4), pp. 441-449.
[11] Kung VL, Ozer EA, Hauser AR. The accessory genome of Pseudomonas aeruginosa.
Microbiology and Molecular Biology Reviews. 2010; 74: 621-641.
[12] Moreau-Marquis S, Stanton BA, O’Toole GA. Pseudomonas aeruginosa biofilm
formation in the cystic fibrosis airway. Pulmonary Pharmacology & Therapeutics.
2008; 21: 595-599.
[13] Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa:
clinical impact and complex regulation of chromosomally encoded resistance
mechanisms. Clinical Microbiology Reviews. 2009; 22(4): 582-610.
[14] Kerr KG, Snelling AM. Pseudomonas aeruginosa: a formidable and ever-present
adversary. Journal of Hospital Infection. 2009; 73: 338-344.
[15] Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant
Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents
Chemother. 2006; 50(1): 43-8.
[16] Gad GF, El-Domany RA, Zaki S, Ashour HM. Characterization of Pseudomonas
aeruginosa isolated from clinical and environmental samples in Minia, Egypt:
prevalence, antibiogram and resistance mechanisms. J Antimicrob Chemother. 2007;
60(5): 1010-7.
[17] Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent
experience with Pseudomonas aeruginosa bacteremia in patients with cancer:
Retrospective analysis of 245 episodes. Arch Intern Med. 2000; 160(4): 501-9.
[18] Hirsch EB, Tam VH. Impact of multidrug-resistant Pseudomonas aeruginosa infection
on patient outcomes. Expert Rev Pharmacoecon Outcomes Res. 2010; 10(4): 441-51.
[19] Maschmeyer G, Braveny I. Review of the incidence and prognosis of Pseudomonas
aeruginosa infections in cancer patients in the 1990s. Eur J Clin Microbiol Infect Dis.
2000; 19(12): 915-25.
[20] Tsukayama DT, van Loon HJ, Cartwright C, Chmielewski B, Fluit AC, van der Werken
C, et al. The evolution of Pseudomonas aeruginosa during antibiotic rotation in a
medical intensive care unit: the RADAR-trial. Int J Antimicrob Agents. 2004; 24(4):
339-345.
[21] Sangeetha Gunalan, Rajeshwari Sivaraj, and Venckatesh Rajendran, Progress in Natural
Science: Materials International. 22(6) (2012) 693.
[22] Mohammad Reza Arefi, Saeed Rezaei-Zarchi, Saber Imani, African Journal of
Biotechnology. 11(34) (2012) 8520.
[23] Siddiqui A, Bernstein J. Chronic wound infection: Facts and controversies. Clin
Dermatol. 2010; 28: 516-26.
[24] Krieg, Noel. Bergey’s Manual of Systematic Bacteriology. Volume 1. Baltimore:
Williams & Wilkins. 1984.
[25] Forbes BA, Sahm DF, Weissfeld AS. Bailey and Scotts’ Diagnostic microbiology 12th
ed. Elsevier 2007.
[26] Perez C., Pauli M. and Bazevque P. (1990). An antibiotic assay by the agar well
diffusion method. Acta Biologiae et Medicine Experimentalis 15, 113-115.
[27] NCCLS (National Committee for Clinical Laboratory Standards): Methods for dilution
antimicrobial susceptibility tests of bacteria that grow aerobically. Approved Standard
M100-S12. Wayne. PA, NCCLS; 2002.
[28] Xi JH, Yeo SY, Lee HJ, Jeong SH,” Preparation of nano composite fibres for permanent
antibacterial effect”, Journal of Material. Science 38 (2003) 2143-2147.
[29] Chwalibog A., Sawosz E., Hotowy A., Szeliga J., Mitura S., Mitura K., Grodzik M.,
Orlowski P. and Sokolowska, A. (2010): Visualization of interaction between inorganic
nano-particles and bacteria or fungi. International Journal of Nanomedicine; 5, 1085–
1094.
[30] Kamellia Nejati, Zolfaghar Rezvani, and Rafat Pakizevand. Synthesis of ZnO
Nanoparticles and Investigation of the Ionic Template Effect on Their Size and Shape.
Int. Nano Lett. 1(2) (2011) 75-81.
[31] Spolenak, R.; Ludwig, W.; Buffiere, J. Y. and Michler, J. In-situ elastic strain
measurements – diffraction and spectroscopy. MRS Bulletin, (2010), 35(5): 368-374
[32] Hong R.Y., Pan T.T., Qian J.Z., Li H.Z., Synthesis and surface modification of ZnO
nanoparticles. Chem. Eng. J. 119 (2006) 71-81.
[33] Sangani MH, Nakhaei Moghaddam M, Forghanifard M. Inhibitory effect of zinc oxide
nanoparticles on Pseudomonas aeruginosa biofilm formation, Nanomed J, (2015); 2(2):
121-128.
[34] Yousef Jehad M., Enas N. Danial. In Vitro Antibacterial Activity and Minimum
Inhibitory Concentration of Zinc Oxide and Nano-particle Zinc oxide Against
Pathogenic Strains, Journal of Health Sciences, (2012), 2(4): 38-42.
[35] Chauhan R., A. Reddy, J. Abraham. Biosynthesis of silver and zinc oxide nanoparticles
using Pichia fermentans JA2 and their antimicrobial property, Appl Nanosci (2015) 5:
63-71.
[36] Voicu G., O. Oprea, B. S. Vasile, E. Anderonescu, ” Antibacterial activity of Zinc
Oxide– Gentamicin hybrid material”, Digest Journal of Nanomaterials and
Biostructures 8(3) (2013) 1191-1203.
[37] Oberdorster G, Maynard A, Donaldson K, Castranova V Principles for characterizing
the potential human health effects from exposure to nanomaterials: elements of a
screening strategy. Part Fibre Toxicol 2 (2005) 8.
[38] Nagarajan P. and Rajagopalan V. (2008). Enhanced bioactivity of ZnO nano-particles in
an antimicrobial study. Environ. Sci. Technol. 9 (035004), 7-15
[39] Saadat M, S.R. Mohammadi and Mehdi Eskandari. Evaluation of Antibacterial Activity
of ZnO and TiO2 Nanoparticles on Planktonic and Biofilm Cells of Pseudomonas
aeruginosa. BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, 10(2) (2013) 629-
635.
[40] Yuan Z ZL. Influence of ZnO+Fe2O3 additives on the anatase-to-rutile transformation
of nanometer TiO2 powders. Nano Struc Mater. 10 (1998) 1127-33.
[41] Jiang JO, G.; Elder, A.; Gelein, R.; Mercer, P.; Biswas. Does nanoparticle activity
depend upon size and crystal phase? Nanotoxicology, 2 (2008) 33-42
Download all article in PDF
